Sofosbuvir may be a potential anti-sars-cov-2 rdrp drug

Mohamed Nabil Ibrahim, Abdo Abdellah Elfiky

Research output: Contribution to journalArticlepeer-review


The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.
Original languageEnglish (US)
Pages (from-to)205-207
Number of pages3
JournalAmerican Journal of Biochemistry and Biotechnology
Issue number2
StatePublished - May 10 2021
Externally publishedYes

Bibliographical note

KAUST Repository Item: Exported on 2022-06-21
Acknowledgements: Computational support from the King Abdullah University of Science and Technology (KAUST HPC allocation grant “K1482”) and COVID-19 Grant by Cairo University , is acknowledged.
This publication acknowledges KAUST support, but has no KAUST affiliated authors.


Dive into the research topics of 'Sofosbuvir may be a potential anti-sars-cov-2 rdrp drug'. Together they form a unique fingerprint.

Cite this